Payment overview · 2025
General Payments
$5,113.27
37 reported records · 12 companies
Healthcare provider profile · identity verified
Zaheed Tai, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · WINTER HAVEN, FL · NPI 1487611299
Verified facts
What the public records show
CMS Open Payments records show Zaheed Tai, D.O. received $5,113.27 in general payments during 2025 across 37 reported records.
AngioDynamics, Inc. accounted for 73.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $3,733.33 | 73.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $757.35 | 14.8% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $207.62 | 4.1% | 13 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $165.65 | 3.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $61.39 | 1.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.38 | 1.1% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $27.00 | 0.5% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $26.82 | 0.5% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $24.68 | 0.5% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $22.92 | 0.5% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $17.52 | 0.3% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $13.61 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $3,733.33 | 1 |
| Food and Beverage | $1,379.94 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $3,733.33 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $165.65 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $99.05 | 5 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $42.11 | 3 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $11.19 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $6.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 724 | 266 |
| Eliquis | Apixaban | 660 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 565 | 207 |
| Entresto | Sacubitril/Valsartan | 451 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 149 |
| Carvedilol | Carvedilol | 384 | 128 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 380 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 124 |
| Metoprolol Tartrate | Metoprolol Tartrate | 341 | 110 |
| Losartan Potassium | Losartan Potassium | 284 | 99 |
| Ranolazine Er | Ranolazine | 184 | 56 |
| Lisinopril | Lisinopril | 173 | 62 |
| Nitroglycerin | Nitroglycerin | 171 | 91 |
| Furosemide | Furosemide | 168 | 59 |
| Brilinta | Ticagrelor | 161 | 52 |
| Xarelto | Rivaroxaban | 160 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 48 |
| Ezetimibe | Ezetimibe | 139 | 45 |
| Farxiga | Dapagliflozin Propanediol | 134 | 30 |
| Jardiance | Empagliflozin | 120 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 104 | 28 |
| Flecainide Acetate | Flecainide Acetate | 103 | 28 |
| Repatha Sureclick | Evolocumab | 98 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 36 |
| Spironolactone | Spironolactone | 96 | 38 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 36 |
| Sotalol | Sotalol Hcl | 85 | 24 |
| Cilostazol | Cilostazol | 84 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 28 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 71 | 16 |
| Potassium Chloride | Potassium Chloride | 66 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 18 |
| Simvastatin | Simvastatin | 50 | 17 |
| Chlorthalidone | Chlorthalidone | 49 | 20 |
| Enalapril Maleate | Enalapril Maleate | 42 | 13 |
| Nexletol | Bempedoic Acid | 37 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Bumetanide | Bumetanide | 35 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | 14 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Famotidine | Famotidine | 22 | 17 |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Prednisone | Prednisone | 19 | 17 |
| Ramipril | Ramipril | 19 | suppressed |
| Dofetilide | Dofetilide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,113.27 · 37 records | AngioDynamics, Inc. | Assure WCD, Auryon Laser System 100-120 Vac, CDS - MCT/CEM Monitoring, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ESPRIT, FLOWTRIEVER CATHETER, S, HI-TORQUE COMMAND, LUX-Dx Insertable Cardiac Monitor, MYCARELINK, OPTIS, Paradise Ultrasound Renal Denervation System, Penumbra System, RotarexS 6 F x 135 cm, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error